Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT141 Phase I/IIa in CLDN18.2-positive Solid Tumors
NCT04683939Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of BNT141 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 3 more (3 arms), sponsored by BioNTech SE. Primary endpoints: Occurrence of Treatment-emergent Adverse Events up to 30 weeks, Occurrence of Dose Reductions and Discontinuation of BNT141 Due to TEAEs up to 30 weeks and 1 more. Started Jan 2022; status: terminated.
02
Drugs
BNT141
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04683939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683939.